Skip to main content
Erschienen in: Pathology & Oncology Research 3/2011

01.09.2011 | Research

Differential Biomarker Expression in Head and Neck Cancer Correlates with Anatomical Localization

verfasst von: László Tamás, Gabriella Szentkúti, Mónika Erős, Kornél Dános, Diána Brauswetter, Béla Szende, Ivett Zsákovics, Tibor Krenács

Erschienen in: Pathology & Oncology Research | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

We tested the expression of known (p16ink4, Ki67, p53, EGFR) and a new immunohistochemical (collagen XVII/BP180) biomarker in head and neck squamous cell carcinomas (SCC) of diverse anatomical localization. Tissue microarrays (TMA) of 124 SCC were created, immunostained, and analyzed following whole slide digitalization using the Pannoramic Scan and the TMA Module software (3DHISTECH Kft, Budapest, Hungary). Statistical analysis of scoring results was carried out using Pearson’s chi-square test. We observed the significant elevation of p16ink4 and Ki67 expression in supraglottic, tonsillar and tonsillo-lingual SCCs compared to those affecting the oral cavity, oropharynx without tonsils, larynx without supraglottis and the hypopharynx. This differential antigen expression may reflect the diverse route of embryologic differentiation followed by the affected regions except those of the tonsils and the supraglottis which show similar antigenic pattern but diverse developmental path. All the other biomarkers tested including p53, collagen XVII and EGFR were detected in the majority of cancers including high grade cases, but did not reveal any significant regional difference. Based on our results oropharyngeal squamous cell carcinomas may not be regarded as one entity. Concerning the oral cavity and the oropharynx, cancers affecting the tonsils (palatine and lingual) show significantly elevated p16ink4 and Ki67 expression; so as the cancers of the supraglottis compared to the rest of larynx. Consequently, tonsillar and supraglottic cancers show similar biomarker profiles. Correlation of differential biomarker expression with diverse biological behavior in head and neck cancers need further investigations.
Literatur
1.
Zurück zum Zitat Répássy G, Cs F-H, Juhász A et al (1998) Expression of invasion markers CD44v6/v3, NM23 and MMP in laryngeal and hypopharyngeal carcinoma. Pathol Oncol Res 4:14–21PubMedCrossRef Répássy G, Cs F-H, Juhász A et al (1998) Expression of invasion markers CD44v6/v3, NM23 and MMP in laryngeal and hypopharyngeal carcinoma. Pathol Oncol Res 4:14–21PubMedCrossRef
2.
Zurück zum Zitat Lukits J, Timár J, Juhász A et al (2001) Progression difference between cancers of the larynx and hypopharynx is not due to tumor size and vascularization. Otolaryngol Head Neck Surg 125:18–22PubMedCrossRef Lukits J, Timár J, Juhász A et al (2001) Progression difference between cancers of the larynx and hypopharynx is not due to tumor size and vascularization. Otolaryngol Head Neck Surg 125:18–22PubMedCrossRef
3.
Zurück zum Zitat Ang KK, Harris J, Wheeler R et al (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363:24–35PubMedCrossRef Ang KK, Harris J, Wheeler R et al (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363:24–35PubMedCrossRef
4.
Zurück zum Zitat Dahlstrand H, Näsman A, Romanitan M et al (2008) Human papillomavirus accounts both for increased incidence and better prognosis in tonsillar cancer. Anticancer Res 28:1133–1138PubMed Dahlstrand H, Näsman A, Romanitan M et al (2008) Human papillomavirus accounts both for increased incidence and better prognosis in tonsillar cancer. Anticancer Res 28:1133–1138PubMed
5.
Zurück zum Zitat Vidal L, Gillison ML (2008) Human papillomavirus in HNSCC: recognition of a distinct disease type. Hematol Oncol Clin North Am 22:1125–1142PubMedCrossRef Vidal L, Gillison ML (2008) Human papillomavirus in HNSCC: recognition of a distinct disease type. Hematol Oncol Clin North Am 22:1125–1142PubMedCrossRef
6.
Zurück zum Zitat Parry D, Bates S, Mann DJ et al (1995) Lack of cyclin D-Cdk complexes in Rb-negative cells correlates with high levels of p16INK4/MTS1 tumour suppressor gene product. EMBO J 14:503–511PubMed Parry D, Bates S, Mann DJ et al (1995) Lack of cyclin D-Cdk complexes in Rb-negative cells correlates with high levels of p16INK4/MTS1 tumour suppressor gene product. EMBO J 14:503–511PubMed
7.
Zurück zum Zitat Andl T, Kahn T, Pfuhl A et al (1998) Etiological involvement of oncogenic human papillomavirus in tonsillar squamous cell carcinomas lacking retinoblastoma cell cycle control. Cancer Res 58:5–13PubMed Andl T, Kahn T, Pfuhl A et al (1998) Etiological involvement of oncogenic human papillomavirus in tonsillar squamous cell carcinomas lacking retinoblastoma cell cycle control. Cancer Res 58:5–13PubMed
8.
Zurück zum Zitat Chung CH, Raben D (2010) p16 expression as a predictive biomarker of hypoxic cell-sensitizing agents in oropharyngeal. Cancer J Clin Oncol 27:4103–4104 Chung CH, Raben D (2010) p16 expression as a predictive biomarker of hypoxic cell-sensitizing agents in oropharyngeal. Cancer J Clin Oncol 27:4103–4104
9.
Zurück zum Zitat Shi W, Kato H, Perez-Ordonez B et al (2009) Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma. J Clin Oncol 27:6213–6221PubMedCrossRef Shi W, Kato H, Perez-Ordonez B et al (2009) Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma. J Clin Oncol 27:6213–6221PubMedCrossRef
10.
Zurück zum Zitat Kong CS, Narasimhan B, Cao H et al (2009) The relationship between human papillomavirus status and other molecular prognostic markers in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 74:553–561PubMedCrossRef Kong CS, Narasimhan B, Cao H et al (2009) The relationship between human papillomavirus status and other molecular prognostic markers in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 74:553–561PubMedCrossRef
11.
Zurück zum Zitat Stelkovics E, Korom I, Marczinovits I et al (2008) Collagen XVII/BP180 protein expression in squamous cell carcinoma of the skin detected with novel monoclonal antibodies in archived tissues using tissue microarrays and digital microscopy. Appl Immunohistochem Mol Morphol 16:433–441PubMedCrossRef Stelkovics E, Korom I, Marczinovits I et al (2008) Collagen XVII/BP180 protein expression in squamous cell carcinoma of the skin detected with novel monoclonal antibodies in archived tissues using tissue microarrays and digital microscopy. Appl Immunohistochem Mol Morphol 16:433–441PubMedCrossRef
12.
Zurück zum Zitat Nilsson K, Svensson S, Landberg G (2004) Retinoblastoma protein function and p16INK4a expression in actinic keratosis, squamous cell carcinoma in situ and invasive squamous cell carcinoma of the skin and links between p16INK4a expression and infiltrative behavior. Mod Pathol 17:1464–1474PubMedCrossRef Nilsson K, Svensson S, Landberg G (2004) Retinoblastoma protein function and p16INK4a expression in actinic keratosis, squamous cell carcinoma in situ and invasive squamous cell carcinoma of the skin and links between p16INK4a expression and infiltrative behavior. Mod Pathol 17:1464–1474PubMedCrossRef
13.
Zurück zum Zitat Ai L, Stephenson KK, Ling W et al (2003) The p16 (CDKN2a/INK4a) tumor-suppressor gene in head and neck squamous cell carcinoma: a promoter methylation and protein expression study in 100 cases. Mod Pathol 16(9):944–950PubMedCrossRef Ai L, Stephenson KK, Ling W et al (2003) The p16 (CDKN2a/INK4a) tumor-suppressor gene in head and neck squamous cell carcinoma: a promoter methylation and protein expression study in 100 cases. Mod Pathol 16(9):944–950PubMedCrossRef
14.
Zurück zum Zitat Weinberger PM, Yu Z, Haffty BG et al (2004) Prognostic significance of p16 protein levels in oropharyngeal squamous cell cancer. Clin Cancer Res 10(17):5684–5691PubMedCrossRef Weinberger PM, Yu Z, Haffty BG et al (2004) Prognostic significance of p16 protein levels in oropharyngeal squamous cell cancer. Clin Cancer Res 10(17):5684–5691PubMedCrossRef
15.
Zurück zum Zitat Aebersold DM, Beer KT, Laissue J et al (2000) Intratumoral microvessel density predicts local treatment failure of radically irradiated squamous cell cancer of the oropharynx. Int J Radiat Oncol Biol Phys 48:17–25PubMedCrossRef Aebersold DM, Beer KT, Laissue J et al (2000) Intratumoral microvessel density predicts local treatment failure of radically irradiated squamous cell cancer of the oropharynx. Int J Radiat Oncol Biol Phys 48:17–25PubMedCrossRef
16.
Zurück zum Zitat Sittel C, Eckel HE, Damm M et al (2000) Ki67 (MIB1), p53, and lewis-X (LeuM1) as prognostic factors of recurrence in T1 and T2 laryngeal carcinoma. Laryngoscope 110:1012–1017PubMedCrossRef Sittel C, Eckel HE, Damm M et al (2000) Ki67 (MIB1), p53, and lewis-X (LeuM1) as prognostic factors of recurrence in T1 and T2 laryngeal carcinoma. Laryngoscope 110:1012–1017PubMedCrossRef
17.
Zurück zum Zitat Somers KD, Merrick MA, Lopez ME et al (1992) Frequent p53 mutations in head and neck cancer. Cancer Res 52(21):5997–6000PubMed Somers KD, Merrick MA, Lopez ME et al (1992) Frequent p53 mutations in head and neck cancer. Cancer Res 52(21):5997–6000PubMed
18.
Zurück zum Zitat Bradford CR, Zhu S, Ogawa H et al (2003) P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines. Head Neck 25(8):654–661PubMedCrossRef Bradford CR, Zhu S, Ogawa H et al (2003) P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines. Head Neck 25(8):654–661PubMedCrossRef
19.
Zurück zum Zitat Cabelguenne A, Blons H, de Waziers I et al (2000) p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series. J Clin Oncol 18(7):1465–1473PubMed Cabelguenne A, Blons H, de Waziers I et al (2000) p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series. J Clin Oncol 18(7):1465–1473PubMed
20.
Zurück zum Zitat Temam S, Flahault A, Périé S et al (2000) p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck. J Clin Oncol 18(2):385–394PubMed Temam S, Flahault A, Périé S et al (2000) p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck. J Clin Oncol 18(2):385–394PubMed
21.
Zurück zum Zitat Ang KK, Berkey BA, Tu X et al (2002) Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62(24):7350–7356PubMed Ang KK, Berkey BA, Tu X et al (2002) Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62(24):7350–7356PubMed
22.
Zurück zum Zitat Kalyankrishna S, Grandis JR (2006) Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 24(17):2666–2672PubMedCrossRef Kalyankrishna S, Grandis JR (2006) Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 24(17):2666–2672PubMedCrossRef
23.
Zurück zum Zitat Grandis JR, Melhem MF, Gooding WE et al (1998) Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90(11):824–832CrossRef Grandis JR, Melhem MF, Gooding WE et al (1998) Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90(11):824–832CrossRef
24.
Zurück zum Zitat Eberhard DA, Johnson BE, Amler LC et al (2005) Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23(25):5900–5909PubMedCrossRef Eberhard DA, Johnson BE, Amler LC et al (2005) Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23(25):5900–5909PubMedCrossRef
25.
Zurück zum Zitat Peták I, Schwab R, Orfi I et al (2010) Integrating molecular diagnostics into anticancer drug discovery. Nat Rev Drug Discov 7:523–535CrossRef Peták I, Schwab R, Orfi I et al (2010) Integrating molecular diagnostics into anticancer drug discovery. Nat Rev Drug Discov 7:523–535CrossRef
26.
Zurück zum Zitat Répássy G, Czigner J, Ribári O et al (1988) The barrier-like role of activated connective tissue against the spread of supraglottic laryngeal carcinoma. Arch Otorhinolaryngol 245:151–154PubMedCrossRef Répássy G, Czigner J, Ribári O et al (1988) The barrier-like role of activated connective tissue against the spread of supraglottic laryngeal carcinoma. Arch Otorhinolaryngol 245:151–154PubMedCrossRef
Metadaten
Titel
Differential Biomarker Expression in Head and Neck Cancer Correlates with Anatomical Localization
verfasst von
László Tamás
Gabriella Szentkúti
Mónika Erős
Kornél Dános
Diána Brauswetter
Béla Szende
Ivett Zsákovics
Tibor Krenács
Publikationsdatum
01.09.2011
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 3/2011
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-011-9376-9

Weitere Artikel der Ausgabe 3/2011

Pathology & Oncology Research 3/2011 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.